Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

被引：0
作者：
Lina Gao
Yun Zhang
Keenan Sterling
Weihong Song
机构：
[1] Jining Medical University,Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of Mental Disorders, Institute of Mental Health, College of Pharmacy
[2] The University of British Columbia,Townsend Family Laboratories, Department of Psychiatry
[3] Xuanwu Hospital,National Clinical Research Center for Geriatric Disorders
[4] Capital Medical University,Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, School of Mental Health and The Affiliated Kangning Hospital
[5] Wenzhou Medical University,undefined
[6] Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine,undefined
[7] Vision and Brain Health),undefined
来源：
Translational Neurodegeneration | / 11卷
关键词：
Brain-derived neurotrophic factor; Alzheimer’s disease; Amyloid β protein; Tau protein; Neuroinflammation; Neuronal apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.
引用
收藏
相关论文
共 2292 条
[1]  
Alzheimer A(1907)Uber eine eigenartige Erkrankung der Hirnrinde Zentralbl Nervenh Psych 18 177-179
[2]  
Liao X(2020)Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene JCI Insight 5 e135119-982
[3]  
Cai F(2017)Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis Acta Neuropathol 133 967-130
[4]  
Sun Z(2020)NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease Signal Transduct Target Ther 5 37-1718
[5]  
Zhang Y(2020)Alzheimer's disease drug development pipeline: 2020 Alzheimers Dement (N Y) 6 e12050-120
[6]  
Wang J(2021)Aducanumab and the FDA—where are we now? Nat Rev Neurol 17 129-2789
[7]  
Jiao B(2021)Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility JAMA 325 1717-18732
[8]  
Zeng J(2017)Islet amyloid polypeptide: another key molecule in Alzheimer's pathogenesis? Prog Neurobiol 153 100-1554
[9]  
Chen L(2008)Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models J Exp Med 205 2781-1375
[10]  
Wang Z(2006)Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression Proc Natl Acad Sci USA 103 18727-90
12345678910